We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-21.81%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$222M
AUM Growth
-$100M
(-31%)
Cap. Flow
-$21.8M
Cap. Flow
% of AUM
-9.81%
Top 10 Holdings %
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9
Avg Time Held
6.3
quarters
Top 10 Avg Time Held
5.5
quarters
Top 20 Avg Time Held
5.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TELA Bio
TELA
|
+$9.68M |
| 2 |
Inhibrx, Inc. Common Stock
INBX
|
+$8.68M |
| 3 |
Cutera, Inc.
CUTR
|
+$7.8M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$1.98M |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
+$1.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chimerix, Inc.
CMRX
|
+$14.4M |
| 2 |
Bicycle Therapeutics
BCYC
|
+$7.68M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.66M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$5.96M |
| 5 |
Cytokinetics
CYTK
|
+$4.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.09B
| $24.3M | 10.94% |
3,332,732
+41,389
| +1% | +$279K |
2018 Q3
15 quarters
|
|
2
Ocular Therapeutix
OCUL
$1.66B
| $24M | 10.83% |
5,974,800
| – | – |
2019 Q1
13 quarters
|
|
3
Codexis
CDXS
$154M
| $13.5M | 6.07% |
1,288,450
-56,550
| -4% | -$709K |
2014 Q1
33 quarters
|
|
4
DELISTED
Crinetics Pharmaceuticals
CRNX
| $12.5M | 5.64% |
671,300
-21,700
| -3% | -$433K |
2021 Q1
5 quarters
|
|
|
5
Cytokinetics
CYTK
$8.73B
| $11.9M | 5.36% |
302,500
-104,000
| -26% | -$4.19M |
2020 Q2
8 quarters
|
|
|
6
TELA Bio
TELA
$48.8M
| $11.5M | 5.19% |
1,643,367
+1,166,367
| +245% | +$9.68M |
2019 Q4
10 quarters
|
|
7
Protara Therapeutics
TARA
$164M
| $8.88M | 4% |
2,684,167
+10,136
| +0.4% | +$37.1K |
2019 Q3
11 quarters
|
|
|
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $8.25M | 3.72% |
206,266
+48,511
| +31% | +$1.88M |
2020 Q3
7 quarters
|
|
9
Kiniksa Pharmaceuticals
KNSA
$6.18B
| $7.89M | 3.56% |
814,250
-298,250
| -27% | -$2.78M |
2020 Q2
8 quarters
|
|
10
DELISTED
Merus
MRUS
| $7.65M | 3.45% |
338,000
| – | – |
2021 Q3
3 quarters
|
|
11
Keros Therapeutics
KROS
$230M
| $7.63M | 3.44% |
276,000
+10,250
| +4% | +$450K |
2021 Q1
5 quarters
|
|
|
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.7M | 3.02% |
+590,000
| New | +$8.68M |
2022 Q2
0 quarters
|
|
13
Eton Pharmaceutcials
ETON
$1.58B
| $6.45M | 2.91% |
2,462,500
+83,225
| +3% | +$279K |
2018 Q4
14 quarters
|
|
14
DELISTED
Xoma
XOMA
| $5.86M | 2.64% |
263,050
-7,950
| -3% | -$163K |
2017 Q1
21 quarters
|
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.58M | 2.52% |
183,750
-223,252
| -55% | -$6.66M |
2021 Q4
2 quarters
|
|
|
16
DELISTED
Cutera, Inc.
CUTR
| $5.54M | 2.5% |
+147,700
| New | +$7.8M |
2022 Q2
0 quarters
|
|
17
DELISTED
Mersana Therapeutics
MRSN
| $4.84M | 2.18% |
41,880
+13,480
| +47% | +$1.27M |
2022 Q1
1 quarter
|
|
18
Vaxcyte
PCVX
$11B
| $4.13M | 1.86% |
190,000
-21,000
| -10% | -$486K |
2020 Q3
7 quarters
|
|
19
Stereotaxis
STXS
$114M
| $3.86M | 1.74% |
2,099,971
-295,629
| -12% | -$707K |
2019 Q3
11 quarters
|
|
20
Edgewise Therapeutics
EWTX
$4.18B
| $3.59M | 1.62% |
451,400
+148,400
| +49% | +$1.12M |
2022 Q1
1 quarter
|
|
21
908 Devices
MASS
$489M
| $3.43M | 1.54% |
166,406
| – | – |
2022 Q1
1 quarter
|
|
|
22
DELISTED
Chimerix, Inc.
CMRX
| $2.97M | 1.34% |
1,430,000
-4,473,450
| -76% | -$14.4M |
2020 Q2
8 quarters
|
|
23
Fortress Biotech
FBIO
$70.4M
| $2.73M | 1.23% |
216,479
-33,521
| -13% | -$497K |
2020 Q2
8 quarters
|
|
24
Celldex Therapeutics
CLDX
$2.31B
| $2.43M | 1.09% |
90,000
-105,500
| -54% | -$3.06M |
2020 Q2
8 quarters
|
|
25
Liquidia Corp
LQDA
$2.48B
| $2.27M | 1.03% |
521,500
+342,700
| +192% | +$1.77M |
2021 Q4
2 quarters
|
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2022 Portfolio in Review
As of Q2 2022, Opaleye Management held 56 positions worth $222M, down 31% from $322M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Opaleye Management withdrew a net $21.8M in Q2 2022, closing 9 positions and reducing 17 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $7.68M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Opaleye Management opened a new position in Inhibrx, Inc. Common Stock worth $6.7M.
- Opaleye Management's largest Q2 2022 buy was Inhibrx, Inc. Common Stock: 590,000 shares worth $6.7M.
- Opaleye Management added most to TELA Bio in Q2 2022, an estimated $9.68M increase.
- Opaleye Management's biggest Q2 2022 reduction was Chimerix, Inc., cutting an estimated $14.4M.
- Opaleye Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $7.68M.
- Opaleye Management's ten largest holdings make up 59% of its $222M portfolio in Q2 2022.
- Opaleye Management opened 11 new positions and closed 9 in Q2 2022.
- Opaleye Management's portfolio value fell 31% quarter-over-quarter to $222M.
Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.